Search results
Showing 16 to 30 of 56 results for trastuzumab
NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous anti-HER2-based regimen in adults. This is because Daiichi Sankyo UK did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA879
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)
Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults.
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a high risk of recurrence, in adults.
Oesophago-gastric cancer: assessment and management in adults (NG83)
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support. It aims to reduce variation in practice through better organisation of care and support, and improve quality of life and survival by giving advice on the most suitable treatments depending on cancer type, stage and location.
Breast cancer (early) - trastuzumab 26 July 2006 TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and...
Breast cancer (early) - trastuzumab 26 July 2006 TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and...
Early and locally advanced breast cancer: diagnosis and management (NG101)
This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.
Awaiting development [GID-TA11110] Expected publication date: TBC
Awaiting development [GID-TA11339] Expected publication date: TBC
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
In development [GID-TA11289] Expected publication date: TBC
Awaiting development [GID-TA11659] Expected publication date: TBC
Awaiting development [GID-TA11403] Expected publication date: TBC